epidermal pentapeptide: consists of amino acids pGlu, Glu, Asp, Ser, Gly with pGlu at N-terminal end [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 129388 |
| MeSH ID | M0144271 |
| Synonym |
|---|
| epp peptide |
| pglu-glu-asp-ser-glyoh |
| epidermal pentapeptide |
| glycine, n-(n-(n-(n-(5-oxo-l-prolyl)-l-alpha-glutamyl)-l-alpha-aspartyl)-l-seryl)- |
| 106678-69-7 |
| pyroglutamyl-glutamyl-aspartyl-seryl-glycine |
| pyroglu-glu-asp-ser-glyoh |
| (3s,6s,9s)-3-(2-carboxyethyl)-6-(carboxymethyl)-9-(hydroxymethyl)-1,4,7,10-tetraoxo-1-((s)-5-oxopyrrolidin-2-yl)-2,5,8,11-tetraazatridecan-13-oic acid |
| (4s)-5-[[(2s)-3-carboxy-1-[[(2s)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxo-4-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid |
| 5-{[3-carboxy-1-({1-[(carboxymethyl)imino]-1,3-dihydroxypropan-2-yl}imino)-1-hydroxypropan-2-yl]imino}-5-hydroxy-4-{[hydroxy(5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl)methylidene]amino}pentanoic acid |
| DTXSID00910074 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 13 (68.42) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||